Amgen Statistics
Total Valuation
Amgen has a market cap or net worth of $201.27 billion. The enterprise value is $247.57 billion.
| Market Cap | 201.27B |
| Enterprise Value | 247.57B |
Important Dates
The last earnings date was Tuesday, February 3, 2026, after market close.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Feb 13, 2026 |
Share Statistics
Amgen has 539.07 million shares outstanding. The number of shares has increased by 0.19% in one year.
| Current Share Class | 539.07M |
| Shares Outstanding | 539.07M |
| Shares Change (YoY) | +0.19% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 81.27% |
| Float | 537.71M |
Valuation Ratios
The trailing PE ratio is 26.24 and the forward PE ratio is 16.69. Amgen's PEG ratio is 3.62.
| PE Ratio | 26.24 |
| Forward PE | 16.69 |
| PS Ratio | 5.47 |
| Forward PS | 5.33 |
| PB Ratio | 23.23 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 24.85 |
| P/OCF Ratio | 20.21 |
| PEG Ratio | 3.62 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.90, with an EV/FCF ratio of 30.56.
| EV / Earnings | 32.11 |
| EV / Sales | 6.74 |
| EV / EBITDA | 14.90 |
| EV / EBIT | 21.39 |
| EV / FCF | 30.56 |
Financial Position
The company has a current ratio of 1.14, with a Debt / Equity ratio of 6.40.
| Current Ratio | 1.14 |
| Quick Ratio | 0.73 |
| Debt / Equity | 6.40 |
| Debt / EBITDA | 3.29 |
| Debt / FCF | 6.84 |
| Interest Coverage | 3.66 |
Financial Efficiency
Return on equity (ROE) is 106.10% and return on invested capital (ROIC) is 18.77%.
| Return on Equity (ROE) | 106.10% |
| Return on Assets (ROA) | 7.93% |
| Return on Invested Capital (ROIC) | 18.77% |
| Return on Capital Employed (ROCE) | 17.78% |
| Weighted Average Cost of Capital (WACC) | 6.43% |
| Revenue Per Employee | $1.17M |
| Profits Per Employee | $244,794 |
| Employee Count | 31,500 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 1.62 |
Taxes
In the past 12 months, Amgen has paid $1.27 billion in taxes.
| Income Tax | 1.27B |
| Effective Tax Rate | 14.09% |
Stock Price Statistics
The stock price has increased by +28.23% in the last 52 weeks. The beta is 0.47, so Amgen's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | +28.23% |
| 50-Day Moving Average | 338.57 |
| 200-Day Moving Average | 305.53 |
| Relative Strength Index (RSI) | 64.09 |
| Average Volume (20 Days) | 3,117,399 |
Short Selling Information
The latest short interest is 13.26 million, so 2.46% of the outstanding shares have been sold short.
| Short Interest | 13.26M |
| Short Previous Month | 13.96M |
| Short % of Shares Out | 2.46% |
| Short % of Float | 2.47% |
| Short Ratio (days to cover) | 5.06 |
Income Statement
In the last 12 months, Amgen had revenue of $36.75 billion and earned $7.71 billion in profits. Earnings per share was $14.23.
| Revenue | 36.75B |
| Gross Profit | 26.01B |
| Operating Income | 11.57B |
| Pretax Income | 8.98B |
| Net Income | 7.71B |
| EBITDA | 16.62B |
| EBIT | 11.57B |
| Earnings Per Share (EPS) | $14.23 |
Balance Sheet
The company has $9.13 billion in cash and $55.44 billion in debt, with a net cash position of -$46.31 billion or -$85.90 per share.
| Cash & Cash Equivalents | 9.13B |
| Total Debt | 55.44B |
| Net Cash | -46.31B |
| Net Cash Per Share | -$85.90 |
| Equity (Book Value) | 8.66B |
| Book Value Per Share | 16.07 |
| Working Capital | 3.57B |
Cash Flow
In the last 12 months, operating cash flow was $9.96 billion and capital expenditures -$1.86 billion, giving a free cash flow of $8.10 billion.
| Operating Cash Flow | 9.96B |
| Capital Expenditures | -1.86B |
| Free Cash Flow | 8.10B |
| FCF Per Share | $15.03 |
Margins
Gross margin is 70.78%, with operating and profit margins of 31.49% and 20.98%.
| Gross Margin | 70.78% |
| Operating Margin | 31.49% |
| Pretax Margin | 24.42% |
| Profit Margin | 20.98% |
| EBITDA Margin | 45.22% |
| EBIT Margin | 31.49% |
| FCF Margin | 22.04% |
Dividends & Yields
This stock pays an annual dividend of $10.08, which amounts to a dividend yield of 2.70%.
| Dividend Per Share | $10.08 |
| Dividend Yield | 2.70% |
| Dividend Growth (YoY) | 5.81% |
| Years of Dividend Growth | 16 |
| Payout Ratio | 67.88% |
| Buyback Yield | -0.19% |
| Shareholder Yield | 2.52% |
| Earnings Yield | 3.83% |
| FCF Yield | 4.02% |
Analyst Forecast
The average price target for Amgen is $338.50, which is -9.34% lower than the current price. The consensus rating is "Hold".
| Price Target | $338.50 |
| Price Target Difference | -9.34% |
| Analyst Consensus | Hold |
| Analyst Count | 17 |
| Revenue Growth Forecast (5Y) | 3.33% |
| EPS Growth Forecast (5Y) | 14.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 22, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 22, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Amgen has an Altman Z-Score of 1.65 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.65 |
| Piotroski F-Score | 7 |